Finance

Lists
Q2 2026 earnings • released • EPS met 0.00% • Revenue beat +91.39%
See results
ROVI:BME
Laboratorios Farmaceuticos ROVI SA
€58.80
+1.20%
(+0.70) 1D
Jul 24, 5:43:12 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ROVI...
Open
€58.30
High
€59.10
Low
€57.50
Mkt. cap
2.98B
Avg. vol.
139.80K
Volume
227.88K
Dividend
1.63%
Quarterly dividend
€0.24
Ex-dividend date
Jul 13, 2026
P/E ratio
22.84
52-wk high
€86.70
52-wk low
€51.65
EPS
€2.57
Shares outstanding
51.24M
No. of employees
2K
Open
€58.30
High
€59.10
Low
€57.50
Mkt. cap
2.98B
Avg. vol.
139.80K
Volume
227.88K
Dividend
1.63%
Quarterly dividend
€0.24
Ex-dividend date
Jul 13, 2026
P/E ratio
22.84
52-wk high
€86.70
52-wk low
€51.65
EPS
€2.57
Shares outstanding
51.24M
No. of employees
2K
News stories
From sources across the web
Profile
Laboratorios Farmaceuticos Rovi SA is a Spanish pharmaceutical company. The company is a member of the IBEX 35 stock market index. Wikipedia
About Laboratorios Farmaceuticos ROVI SA
CEO-
Employees2K
Founded1946
Headquarters-
SectorPharmaceutical industry
Websiterovi.es
Last report
Jul 23, 2026
Fiscal period
Q2 2026
EPS / Est. (EUR)
€1.46 / -
0.00%miss
Revenue / Est. (EUR)
344.16M / 179.82M
+91.39%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
210.47M
218.42M
152.49M
191.67M
Cost of goods sold
62.66M
90.33M
59.61M
60.04M
Cost of revenue
62.66M
90.33M
59.61M
60.04M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
34.66M
55.40M
38.04M
47.22M
Operating expense
79.83M
73.16M
83.00M
113.58M
Total operating expenses
142.49M
163.49M
142.61M
173.62M
Operating income
67.98M
54.93M
9.89M
18.05M
Other non operating income
8.35M
3.80M
2.32M
10.64M
EBT including unusual items
75.70M
57.94M
12.29M
89.28M
EBT excluding unusual items
75.70M
57.94M
12.29M
26.93M
Income tax expense
17.68M
15.29M
2.84M
14.35M
Effective tax rate
23.36%
26.39%
23.11%
16.07%
Other operating expenses
37.70M
9.61M
36.79M
56.55M
Net income
58.03M
42.68M
9.48M
75.00M
Net profit margin
27.57%
19.54%
6.22%
39.13%
Earnings per share
-
-
-
-
Interest and investment income
86.00K
-
403.00K
-
Interest expense
-757.00K
-767.00K
-782.00K
-2.38M
Net interest expenses
-671.00K
-767.00K
-379.00K
-2.38M
Depreciation and amortization charges
7.47M
8.16M
8.17M
9.81M
EBITDA
79.21M
55.10M
18.05M
27.85M
Gain or loss from assets sale
-
14.00K
1.77M
-2.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer